MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
March 08 2023 - 8:00AM
MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell-based therapeutics and to
support innovative, cell-based research, today announced the
formation of its new Scientific Advisory Board (SAB) that will
reflect the cutting edge of research in molecular design and cell
engineering, as well as a deep understanding of translational
development, in order to leverage the benefits of impactful
discoveries for therapeutic applications.
“With the formation of our Scientific Advisory Board, we are
expanding the depth and breadth of our leadership team and
scientific expertise with the next generation of leaders in the
field of gene and cell therapy,” said Doug Doerfler,
President and CEO of MaxCyte. “These four dynamic
scientists are deeply connected in the scientific community through
their work and memberships in professional societies and will bring
the innovation and support needed to nurture our early-stage
projects from beginning to end.”
Each of these individuals has a unique background and brings a
diverse scientific perspective. Supported by deep technical
knowledge, the SAB will help us unlock the power of cells, which
will enhance our R&D activities and portfolio,” said
Cenk Sumen, PhD, Chief Scientific Officer of
MaxCyte. “With the SAB’s guidance, we aim to provide our
clients with innovative cell engineering applications that
accelerate the development of novel therapies to improve patient
outcomes.”
Members of the MaxCyte Scientific Advisory Board
include:
Oliver Rando, MD, PhD, is a professor in the
Biochemistry and Molecular Biotechnology Department at the
University of Massachusetts Worcester T.H. Chan School of Medicine
and principal investigator within the Rando Lab, which is focused
on genomic approaches to chromatin structure and function, as well
as epigenetic inheritance. He completed his PhD and MD at Stanford
University in Palo Alto, California, working on chromatin
remodeling and T-cell activation in the lab of Jerry Crabtree. Dr.
Rando received a Bachelor of Arts in Biochemistry from Harvard
University in Cambridge, Massachusetts while working on the role of
the proteasome in activation of NF-kB in the lab of Tom
Maniatis.
Marcela Maus, MD, PhD, FABIM, is an associate
professor of medicine at Harvard Medical School and the director of
Cellular Immunotherapy at Massachusetts General Hospital Cancer
Center. She oversees the Maus Lab, which evaluates next-generation,
genetically modified CAR T-cells as immunotherapy in patients with
hematologic malignancies and solid tumors. Dr. Maus holds graduate
degrees (M.D., Ph.D.) from University of Pennsylvania, where she
completed graduate training with Dr. Carl June. Dr. Maus then
trained in internal medicine at University of Pennsylvania and in
hematology and medical oncology at Memorial Sloan Kettering Cancer
Center. She also received a BS in Biology and Literature from
Massachusetts Institute of Technology.
Avery Posey, PhD, is an assistant professor in
the Department of Systems Pharmacology and Translational
Therapeutics at the University of Pennsylvania Perelman School of
Medicine. The Posey Lab focuses on the development of novel targets
for CAR-T cell therapies, strategies to enhance the functional
persistence of CAR-T cells, and the impact of changes in
glycosylation on the tumor immune microenvironment. Dr. Posey holds
a PhD in Genetics from the University of Chicago, and two BS
degrees in Biochemistry and Bioinformatics from the University of
Maryland, Baltimore County (UMBC). He completed his postdoctoral
training in the laboratory of Carl June, where he generated
glycosylation-specific chimeric antigen receptors to precisely
target tumor-glycoforms of MUC1.
Nako Nakatsuka, PhD is a senior
scientist/principal investigator in the Laboratory of Biosensors
and Bioelectronics at ETH Zurich in Switzerland, whose research is
focused on harnessing artificial DNA-based receptors called
aptamers for small-molecule biosensing. Aptamers are integrated
into nanoscale biosensors to monitor neurotransmitters with the
goal of unraveling the basic mechanisms of neurodegenerative
diseases. Beyond neuroscience, novel aptamer-based biosensors are
being developed with the vision of translation for personalized
medicine. Dr. Nakatsuka completed her PhD in Chemistry at the
University of California, Los Angeles, while working in the labs of
Anne Andrews and Paul Weiss. Her thesis exploited aptamers to
overcome the conventional bottlenecks of electronic biosensing of
small molecules in complex biological environments. She also joined
the bionanotechnology research lab of Professor Ipsita Banerjee at
Fordham University in New York while completing her BS degree in
Chemistry.
About MaxCyteMaxCyte is a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research. Over the past 20 years, we
have developed and commercialized our proprietary Flow
Electroporation® technology, which facilitates complex engineering
of a wide variety of cells. Our ExPERT™ platform, which is based on
our Flow Electroporation technology, has been designed to support
the rapidly expanding cell therapy market and can be utilized
across the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx®, STx® GTx® and VLx™;
a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. Learn more at
maxcyte.com and follow us on Twitter and LinkedIn.
MaxCyte Contacts:
US IR AdviserGilmartin
GroupDavid Deuchler, CFA+1 415-937-5400ir@maxcyte.com
US Media RelationsSpectrum Seismic
CollaborativeValerie Enes+1
408-497-8568valerie@spectrumscience.com
Nominated Adviser and Joint Corporate
BrokerPanmure GordonEmma Earl / Freddy CrossleyCorporate
BrokingRupert Dearden+44 (0)20 7886 2500
UK IR AdviserConsilium Strategic
CommunicationsMary-Jane ElliottChris Welsh+44 (0)203 709
5700maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCN)
Historical Stock Chart
From Jul 2023 to Jul 2024